Duality Biotherapeutics, a company dedicated to the development of antibody- drug conjugate (ADC), passed the listing hearing of the Stock Exchange, with Morgan Stanley, Jefferies and CITIC Securities being its joint sponsors.

Duality Biotherapeutics has self-discovered two core products, namely DB-1303/BNT323 and DB-1311/BNT324, as well as five other clinical-stage ADCs, two bispecific ADCs and multiple other preclinical ADCs, according to the preliminary prospectus information after the hearing.

Currently, 5 of its clinical-stage assets have obtained investigational new drug approvals from both the US Food and Drug Administration (FDA) and China's National Medical Products Administration (NMPA).